Susquehanna International Group, LLP Surface Oncology, Inc. Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	BUY	$1.42 - $3.15 $61,486 - $136,395	43,300 Added 390.09%	54,400 $89,000
Q1 2022 May 16, 2022	SELL	$2.65 - $5.08 $29,415 - $56,388	-11,100 Reduced 50.0%	11,100 $33,000
Q4 2021 Feb 14, 2022	SELL	$4.73 - $7.9 $403,469 - $673,870	-85,300 Reduced 79.35%	22,200 $106,000
Q3 2021 Nov 15, 2021	SELL	$5.16 - $7.98 $518,064 - $801,192	-100,400 Reduced 48.29%	107,500 $814,000
Q2 2021 Aug 11, 2021	BUY	$6.45 - $9.09 $516,000 - $727,200	80,000 Added 62.55%	207,900 $1.55 Million
Q1 2021 May 17, 2021	BUY	$7.25 - $13.82 $353,800 - $674,416	48,800 Added 61.69%	127,900 $998,000
Q4 2020 Feb 16, 2021	BUY	$6.87 - $10.48 $543,417 - $828,968	79,100 New	79,100 $731,000

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.